Do not equate all trials as the same, this is important though.
ACW also at a lower market cap than IHL initially.
We have four Phase 2As, which is extremely impressive.
Each represent 4 novel markets where we can sell our products through CannVaLate, each worth billions.
Sleep Apnea is the exciting one that could really create a multibag immediately off the back of the results because there is no such medicinal cure for the problem, besides the existing CPAP ResMed MACHINES, not oral substances like we are trying.
Generally, IMO the big bang trial results happen when the trial in question is something revolutionary to its field where the assumed product that will be created afterwards will face little to no competition in a large market.
DYOR. IMO risk/reward is really good here. You have 4 different chances, and as has been posted earlier our novel dronabinol IHL-42X has ALREADY SUCCEEDED in America. However, our American peers in RespireRX do not have the license in Australia, whereas we will.
Our Med Board comprises of a medical expert for each area (Perionditis, Sleep Apnea, TMJ, Concussion) who all have options that unlock at 200M MC, so having such a qualified team seriously ups the PROBABILITY of our trials being successful.
Trading and Investing anything at the end of the day involves a lot of probability, as Nassim Taleb would ramble on about. For IHL, IMO the probability of success and further multibags (I have already made multibags on this) is extremely high. Think people have a very short term memory because the amount that this BOD has been able to accomplish in a short span of time is seriously impressive. Most specs have dodgy or just incompetent boards and at the end of the day, the CREAM rises to the top. DYOR, but there is so much info out there now that you can easily come to the conclusion that IHL is an high probability opportunity, especially when compared to other bios.
Expand